180 related articles for article (PubMed ID: 9218104)
1. Expression of adhesion molecules in malignant plasma cells in multiple myeloma: comparison with normal plasma cells and functional significance.
Helfrich MH; Livingston E; Franklin IM; Soutar RL
Blood Rev; 1997 Mar; 11(1):28-38. PubMed ID: 9218104
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44.
Vacca A; Di Loreto M; Ribatti D; Di Stefano R; Gadaleta-Caldarola G; Iodice G; Caloro D; Dammacco F
Am J Hematol; 1995 Sep; 50(1):9-14. PubMed ID: 7545353
[TBL] [Abstract][Full Text] [Related]
3. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
[TBL] [Abstract][Full Text] [Related]
4. The involvement of adhesion molecules in the biology of multiple myeloma.
Van Riet I; Van Camp B
Leuk Lymphoma; 1993 Apr; 9(6):441-52. PubMed ID: 8339050
[TBL] [Abstract][Full Text] [Related]
5. Adhesive interactions between tumour cells and bone marrow stromal elements in human multiple myeloma.
Faid L; Van Riet I; De Waele M; Facon T; Schots R; Lacor P; Van Camp B
Eur J Haematol; 1996 Nov; 57(5):349-58. PubMed ID: 9003475
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.
Zannettino AC; Farrugia AN; Kortesidis A; Manavis J; To LB; Martin SK; Diamond P; Tamamura H; Lapidot T; Fujii N; Gronthos S
Cancer Res; 2005 Mar; 65(5):1700-9. PubMed ID: 15753365
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD21 antigen on myeloma cells and its involvement in their adhesion to bone marrow stromal cells.
Huang N; Kawano MM; Mahmoud MS; Mihara K; Tsujimoto T; Niwa O; Kuramoto A
Blood; 1995 Jun; 85(12):3704-12. PubMed ID: 7780154
[TBL] [Abstract][Full Text] [Related]
8. Adhesion of multiple myeloma cells to the bone marrow microenvironment: implications for future therapeutic strategies.
Vidriales MB; Anderson KC
Mol Med Today; 1996 Oct; 2(10):425-31. PubMed ID: 8897437
[TBL] [Abstract][Full Text] [Related]
9. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
10. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.
Hurt EM; Wiestner A; Rosenwald A; Shaffer AL; Campo E; Grogan T; Bergsagel PL; Kuehl WM; Staudt LM
Cancer Cell; 2004 Feb; 5(2):191-9. PubMed ID: 14998494
[TBL] [Abstract][Full Text] [Related]
12. Cell surface expression and functional significance of adhesion molecules on human myeloma-derived cell lines.
Kim I; Uchiyama H; Chauhan D; Anderson KC
Br J Haematol; 1994 Jul; 87(3):483-93. PubMed ID: 7993788
[TBL] [Abstract][Full Text] [Related]
13. Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma.
Neri P; Bahlis NJ
Curr Cancer Drug Targets; 2012 Sep; 12(7):776-96. PubMed ID: 22671924
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.
Klein B; Seckinger A; Moehler T; Hose D
Recent Results Cancer Res; 2011; 183():39-86. PubMed ID: 21509680
[TBL] [Abstract][Full Text] [Related]
15. Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma.
Thomas X; Anglaret B; Magaud JP; Epstein J; Archimbaud E
Leuk Lymphoma; 1998 Dec; 32(1-2):107-19. PubMed ID: 10037006
[TBL] [Abstract][Full Text] [Related]
16. Adhesion molecules--The lifelines of multiple myeloma cells.
Katz BZ
Semin Cancer Biol; 2010 Jun; 20(3):186-95. PubMed ID: 20416379
[TBL] [Abstract][Full Text] [Related]
17. N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.
Groen RW; de Rooij MF; Kocemba KA; Reijmers RM; de Haan-Kramer A; Overdijk MB; Aalders L; Rozemuller H; Martens AC; Bergsagel PL; Kersten MJ; Pals ST; Spaargaren M
Haematologica; 2011 Nov; 96(11):1653-61. PubMed ID: 21828122
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow microenvironment and the progression of multiple myeloma.
Caligaris-Cappio F; Gregoretti MG; Merico F; Gottardi D; Ghia P; Parvis G; Bergui L
Leuk Lymphoma; 1992 Sep; 8(1-2):15-22. PubMed ID: 1493467
[TBL] [Abstract][Full Text] [Related]
19. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
Tian E; Zhan F; Walker R; Rasmussen E; Ma Y; Barlogie B; Shaughnessy JD
N Engl J Med; 2003 Dec; 349(26):2483-94. PubMed ID: 14695408
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.
Corso A; Ferretti E; Lazzarino M
Hematology; 2005 Jun; 10(3):215-24. PubMed ID: 16019470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]